Project Grant F32CA288044
Award Date
9/6/24
Completion Date
5/31/27
Dollars Obligated
$365K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $577,634 Project Grant to Northwestern University to investigate the role of the SEC61 complex in overcoming resistance to immunotherapy in glioblastoma (GBM), an incurable brain cancer. The research aims to understand how overexpression of the SEC61G subunit contributes to GBM's resistance to T cell-mediated immunotherapies, and to evaluate SEC61G as a potential therapeutic target...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $417,858 to Brigham & Women's Hospital Inc. to develop a novel cellular therapy platform for the treatment of glioblastoma, a highly malignant brain cancer. The project aims to engineer mesenchymal stem cells (MSCs) to release bi-specific T-cell engager (BiTE) molecules targeting multiple tumor antigens (EGFR, EGFRvIII, IL13RA2) and co-express IL-12 and immune checkpoint inhibitors....
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This Project Grant award, valued at $639,004 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to evaluate the safety and efficacy of a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key research activities include: Collecting and analyzing pre- and post-treatment tumor tissue and peripheral blood samples to conduct comprehensive immuno-profiling using advanced...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $633,656 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Brigham & Women's Hospital Inc. to improve intratumoral IL12 immunogene therapy for glioblastoma based on human clinical trial results. The project aims to: 1) compare the efficacy, tolerability, and immune effects of neoadjuvant vs. adjuvant anti-PD1 therapy in mouse models of glioblastoma treated...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $645,873 to The University of Texas M.D. Anderson Cancer Center to develop a novel approach for producing chimeric antigen receptor (CAR) macrophages in vivo using mRNA-loaded extracellular vesicles. The goal is to evaluate the feasibility and antitumor efficacy of this approach against glioblastoma, the most common and lethal primary central nervous system cancer in adults. The...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This $451,996 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a collaboration between the University of Texas at Arlington, the University of Oklahoma Health Sciences Center, and the University of Texas Southwestern Medical Center to develop high-throughput platforms for identifying and validating drugs that can target migrating and treatment-resistant glioblastoma (GBM) cancer cells. The key objectives are to (1) employ an ex vivo...